cGMP signaling as a target for the prevention and treatment of breast cancer

Semin Cancer Biol. 2015 Apr:31:106-10. doi: 10.1016/j.semcancer.2014.06.006. Epub 2014 Jun 24.

Abstract

One in eight women in the United States will be diagnosed with invasive breast cancer in her lifetime. Advances in therapeutic strategies, diagnosis, and improved awareness have resulted in a significant reduction in breast cancer related mortality. However, there is a continued need for more effective and less toxic drugs for both the prevention and the treatment of breast cancer in order to see a continued decline in the morbidity and mortality associated with this disease. Recent studies suggest that the cGMP signaling pathway may be aberrantly regulated in breast cancer. As such, this pathway may serve as a source of novel targets for future breast cancer drug discovery efforts. This review provides an overview of cGMP signaling in normal physiology and in breast cancer as well as current strategies being investigated for targeting this pathway in breast cancer.

Keywords: Breast cancer; GC; NSAID; PKG; cGMP.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / prevention & control*
  • Cyclic GMP / metabolism*
  • Female
  • Guanosine Triphosphate / metabolism
  • Guanylate Cyclase / metabolism
  • Humans
  • Models, Biological
  • Signal Transduction / drug effects*

Substances

  • Antineoplastic Agents
  • Guanosine Triphosphate
  • Guanylate Cyclase
  • Cyclic GMP